Loading company…
Incheon biotech company developing stem cell isolation and production technology for immune-related conditions.
Founded in 2014 and based in Incheon, South Korea, SCM Lifescience develops stem cell isolation and stem cell production technology for patients with immunological conditions, including graft-versus-host disease, atopic dermatitis, acute pancreatitis, diabetes and asthma. In June 2020 it raised KRW 30.6 billion in an IPO, selling 1.8 million shares at KRW 17,000 each on KOSDAQ.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in